Enanta Pharmaceuticals, Inc.
ENTA
$8.67
$0.020.23%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 22.70% | -11.99% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 22.70% | -11.99% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 22.70% | -11.99% | |||
| SG&A Expenses | -12.21% | -11.35% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.69% | -2.59% | |||
| Operating Income | 22.97% | -4.18% | |||
| Income Before Tax | 23.90% | -5.47% | |||
| Income Tax Expenses | 102.22% | -213.70% | |||
| Earnings from Continuing Operations | 19.38% | -1.59% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 19.38% | -1.59% | |||
| EBIT | 22.97% | -4.18% | |||
| EBITDA | 24.19% | -2.96% | |||
| EPS Basic | 19.46% | -1.04% | |||
| Normalized Basic EPS | 23.97% | -7.90% | |||
| EPS Diluted | 19.46% | -1.04% | |||
| Normalized Diluted EPS | 23.97% | -7.90% | |||
| Average Basic Shares Outstanding | 0.10% | 0.55% | |||
| Average Diluted Shares Outstanding | 0.10% | 0.55% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||